Featuring the major pharmaceutical, medical device and regulatory agencies across Europe, Health Network Communications will present Pharma Compliance 2013 taking place at The Royal Horseguards Hotel in London on 24-26th September.
This 3 day conference brings together over 30 top Pharma and regulatory experts that will provide fresh insights and best practices in achieving a culture of compliance. The agenda is packed full of ideas, case studies and innovative people which are ready to inspire you, your organisation and your strategy.
Kristine Aachmann Beth, Corporate Counsel, Novo Nordisk A/S will be presenting on Tuesday, 24th September on “Effective development and implementation of a compliance programme that works for your organisation.” Also on Tuesday, understand “How to structure and manage your legal and compliance teams internationally” from Ana Gonzalez Prada, EMEA Corporate Counsel, Ethics & Compliance, Baxter Healthcare.
A host of speakers will be available to learn and network with across the three day conference including Sigrid Willame, Vice President, Compliance Officer, GSK Biologics, Peter Herrmann Corporate Compliance Officer, Actelion, Andrea Chard, Chief Privacy Officer, AstraZeneca, and Richard Bergström, Director General, EFPIA.
A host of different case studies and real world examples will be given on operational compliance best practices, transparency, disclosure and aggregate spend requirements, anti-bribery, corruption and due diligence and compliant communication and promotion. Best rates to attend the conference are available before the 16th August, and start at £1,450. For more information regarding the conference, please go to http://www.healthnetworkcommunications.com/compliance
Press passes are also available, but limited. Please contact Justine Williams at [email protected] for more information.
Pharma Compliance 2013
24-26th September 2013
The Royal Horseguards Hotel
Health Network Communications
The Life Sciences sector is undergoing unprecedented change; technological advances and regulatory harmonisation have been coupled with rising R&D costs, decreasing productivity and high profile product failures. The traditional business model for the development of medicines has never been under greater scrutiny as academia, CROs and biotechnology organisations change the way healthcare products are developed and delivered.
Through our network of advisors within industry, academia and regulatory authorities we are able to develop events that provide solutions to some of the most pressing issues in the sector today and deliver cost effective networking opportunities that give our clients the ability to make informed decisions.
Our team is comprised of some of the most experienced event producers within the Life Science sector. Underpinning all our work is a commitment to quality, through programme design, marketing, logistics and customer service.